Intuitive Surgical’s AI Vision Can’t Break the Stock’s Downward Spiral
Published on 07/24/2026 at 06:53 | Redaktion boerse-global.de
The disconnect between Intuitive Surgical’s operational strength and its stock price has rarely been starker. On Thursday, shares of the robotic surgery pioneer tumbled another 2.38% to close at €291.75, having earlier touched a fresh 52-week low of €289.05. That leaves the stock down 40.36% since the start of the year and roughly 30% below its 200-day moving average of €418.10.
The selling pressure has pushed the 14-day relative strength index to 29.3, deep in oversold territory where traders typically anticipate a bounce. Yet no rebound has materialized, underscoring just how wide the gulf has become between the company’s financial performance and market sentiment.
Strong Quarter, Cautious Guidance
Intuitive Surgical’s second-quarter results, released weeks ago, were anything but weak. Revenue climbed 18.5% to $2.89 billion, while adjusted earnings per share came in at $2.80 — both comfortably ahead of analyst estimates. The installed base of da Vinci systems expanded 12% year-over-year to 11,710 units, with 246 of the new da Vinci 5 platforms shipped in the quarter alone.
The rub came from management’s forward view. The board declined to raise its full-year procedure-growth forecast, keeping it at 13.5% to 15.5% for 2026. The culprit: the expiration of enhanced tax credits under the Affordable Care Act, which the company described as having a “moderately negative effect” on elective procedures during the quarter. Rising costs for semiconductor components and freight rates are also squeezing near-term margin expectations, even as the underlying business performs well.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Recurring revenue from instruments, accessories, and services accounted for roughly 85% of total second-quarter sales — the classic flywheel effect that long-term investors prize. The balance sheet remains fortress-like, with approximately $8.6 billion in cash and investments and zero conventional debt.
AI Roadshow Meets a Cold Market
On July 23, Intuitive Surgical used the SRS 2026 conference to unveil a five-tier artificial intelligence framework built on data from more than 20 million da Vinci procedures. The architecture ranges from basic data capture through intraoperative guidance and enhanced dexterity, with “supervised autonomy” as the long-term ambition. CEO Dave Rosa said the AI is designed to shorten surgeons’ learning curves and improve care quality. The presentation culminated in a live telesurgery demonstration connecting Sunnyvale and Atlanta.
The same day, the company also received FDA clearance for its AirSeal system. But none of that technological momentum translated into share-price support.
A Rival’s FDA Nod Adds to the Gloom
Compounding the stock’s woes, the FDA on July 23 also cleared Johnson & Johnson’s Ottava Robotic Surgical System for multiple soft-tissue procedures, including gastric bypass and gallbladder removal. J&J plans an initial commercial launch with select U.S. customers. While J.P. Morgan analysts still view da Vinci as the preferred system in the robotic surgery market, the entry of a healthcare heavyweight adds a new layer of uncertainty.
Momentis Surgical also secured FDA clearance the same day for the multiport configuration of its Anovo robot, which combines natural-orifice, single-port, and multiport capabilities on one platform. The competitive field is visibly thickening, even if Intuitive Surgical’s installed base and brand remain dominant — as evidenced by the recent deployment of a da Vinci Xi system for thoracic surgery at Surrey Memorial Hospital in Canada.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
Institutional Buyers Step In
Retail sentiment has soured, but some institutional investors see opportunity. Dimensional Fund Advisors increased its stake in Intuitive Surgical, according to a July 23 filing — a signal that long-term-focused money still believes in the business model. The company’s market capitalization currently stands at roughly €109.6 billion.
Zacks Equity Research has weighed in on whether Wall Street analysts still view the stock as attractive despite the selloff, a sign that the fundamental valuation debate is heating up as the price falls. For now, the market is weighing the company’s financial substance against near-term headwinds from the ACA effect and intensifying competition — and the scales have yet to tip back in Intuitive Surgical’s favor.
Ad
Intuitive Surgical Stock: New Analysis - 24 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
